Trial Profile
A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL [high-density lipoprotein cholesterol] Levels
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dalcetrapib (Primary) ; Atorvastatin
- Indications Lipid metabolism disorders
- Focus Therapeutic Use
- Sponsors Akros Pharma
- 28 Jun 2008 New trial record.